2024 annual report of interventional treatment for heart failure
10.3969/j.issn.1004-8812.2025.10.006
- VernacularTitle:心力衰竭介入治疗2024年度进展
- Author:
Chang-dong ZHANG
1
;
Yu-cheng ZHONG
;
Geng LI
;
Jie WU
;
Jun TIAN
;
Zhi-cheng JING
;
Wei MA
;
Nian-guo DONG
;
Yong-jian WU
;
Da-xin ZHOU
;
Xiao-ke SHANG
Author Information
1. 华中科技大学同济医学院附属协和医院心脏大血管外科,湖北武汉 430022
- Publication Type:Journal Article
- Keywords:
Heart failure;
Interventional therapy;
Structural intervention;
Cardiac remodeling;
Cardiomyopathy;
Atrial shunt;
Left ventricular assist device;
Pressure monitoring
- From:
Chinese Journal of Interventional Cardiology
2025;33(10):581-587
- CountryChina
- Language:Chinese
-
Abstract:
China has become the country with the highest global burden of heart failure(HF).Despite the widespread use of prognostic-improving medications today,the mortality rate of HF remains high,reaching 13.7％at one year-particularly among patients with heart failure with reduced ejection fraction(HFrEF).HF interventional device therapy(structural intervention)targets the structural factors underlying HF,including atrial pressure,ventricular remodeling,and valvular intervention.It leverages the heart's intrinsic physiological properties and pathological progression mechanisms to deliver treatments through interventions without external active forces,achieving anatomical or functional repair.This field has emerged as a rapidly growing area and plays an increasingly critical role in HF management.This article provides a comprehensive review and summary of the latest advancements in HF and cardiomyopathy interventional therapy over the past year.It covers various novel technologies and products currently in the research phase,aiming to provide an in-depth analysis of the current status and future directions of HF interventional therapy,and further advance the development of this discipline.
